More about

Atezolizumab

News
March 27, 2023
2 min read
Save

Outcomes after first-line therapy for small cell lung cancer may vary by trial eligibility

Outcomes after first-line therapy for small cell lung cancer may vary by trial eligibility

Overall treatment outcomes among patients with extensive-stage small cell lung cancer who received first-line chemoimmunotherapy appeared comparable to those reported in pivotal clinical trials, according to study results.

News
March 10, 2023
3 min read
Save

Atezolizumab may benefit some patients with metastatic urothelial carcinoma, high PD-L1 expression

Atezolizumab may benefit some patients with metastatic urothelial carcinoma, high PD-L1 expression

SAN FRANCISCO — Atezolizumab monotherapy improved OS compared with chemotherapy among patients with PD-L1-high, cisplatin-ineligible metastatic urothelial carcinoma, according to an exploratory analysis of a randomized phase 3 study.

News
February 21, 2023
3 min read
Save

Findings from negative urothelial carcinoma trial suggest ‘chemotherapy backbone matters’

Findings from negative urothelial carcinoma trial suggest ‘chemotherapy backbone matters’

SAN FRANCISCO — The addition of atezolizumab to platinum-based chemotherapy failed to significantly improve survival for patients with metastatic urothelial carcinoma, according to a final analysis of the randomized phase 3 IMvigor130 trial.

News
January 19, 2023
1 min read
Save

Adjuvant combination reduces recurrence risk in early liver cancer

Adjuvant combination reduces recurrence risk in early liver cancer

Adjuvant therapy with atezolizumab and bevacizumab reduced recurrence risk compared with active surveillance for patients with certain types of early-stage liver cancer, according to topline data released by the agents’ manufacturer.

News
January 14, 2023
1 min read
Save

Cervical cancer: Novel therapies, screening interventions provide hope for progress

Cervical cancer: Novel therapies, screening interventions provide hope for progress

Cervical Cancer Awareness Month is observed every January.

News
December 15, 2022
2 min read
Save

Atezolizumab-bevacizumab confers ‘much higher than usual’ survival rates in NSCLC subset

Atezolizumab-bevacizumab confers ‘much higher than usual’ survival rates in NSCLC subset

The addition of atezolizumab to bevacizumab showed promising efficacy among patients with nonsquamous non-small cell lung cancer with high tumor mutational burden, according to results of a phase 2 trial published in JAMA Oncology.

News
December 12, 2022
1 min read
Save

FDA approves Tecentriq for unresectable or metastatic alveolar soft part sarcoma

FDA approves Tecentriq for unresectable or metastatic alveolar soft part sarcoma

The FDA approved atezolizumab for adults and children aged 2 years or older with unresectable or metastatic alveolar soft part sarcoma.

News
November 29, 2022
1 min read
Save

Immunotherapy added to BRAF/MEK inhibitor improves OS for anaplastic thyroid cancer

The triplet combination of vemurafenib/cobimetinib/atezolizumab showed improvement in overall survival in patients with BRAF-mutated anaplastic thyroid cancer, according to research presented at American Thyroid Association Annual Meeting.

News
November 29, 2022
1 min read
Save

Roche withdraws atezolizumab indication for urothelial carcinoma

Roche withdraws atezolizumab indication for urothelial carcinoma

Roche voluntarily withdrew atezolizumab’s indication in the United States for the treatment of adults with locally advanced or metastatic urothelial carcinoma.

News
September 08, 2022
2 min watch
Save

VIDEO: ‘Fine-tuned’ data from IMpower010 shows OS benefit for subset of patients

VIDEO: ‘Fine-tuned’ data from IMpower010 shows OS benefit for subset of patients

At this year’s International Association for the Study of Lung Cancer World Conference on Lung Cancer, one of the more talked about presentations was IMpower010.

View more